Dr. Reddy's Challenges All Four TONMYA Patents Eleven Months After Launch

Tonix Pharmaceuticals is a commercial-stage biotech focused on fibromyalgia, CNS conditions, and an early-stage pipeline spanning Lyme disease prevention, immunology, and oncology. With a market cap of approximately $158 million, it is a small company operating at a significant financial deficit, having reported a net loss of approximately $118.9 million for the full year 2025 against net revenue of approximately $13.1 million from its marketed products.

The company's financial position has historically required repeated equity raises to sustain operations. As of March 31, 2026, Tonix held approximately $185.5 million in cash and cash equivalents, but net cash used in operating activities for Q1 2026 was approximately $40.2 million — more than double the $16.6 million consumed in Q1 2025. Management's guidance, combined with $17.4 million in net proceeds raised from equity offerings in Q2 2026, projects the cash runway only into the second quarter of 2027. Notably, Tonix's former auditor EisnerAmper LLP included in its audit reports for both the years ended December 31, 2024 and December 31, 2025 an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern. Tonix replaced EisnerAmper with PricewaterhouseCoopers LLP in March 2026.

TONMYA — cyclobenzaprine hydrochloride sublingual tablets, 2.8 mg — is the company's lead commercial product and its primary revenue growth driver. It became commercially available at U.S. pharmacies by prescription on November 17, 2025, and generated approximately $1.4 million in its first six weeks on market. Revenue grew to approximately $3.7 million in Q1 2026. By late September 2026, TONMYA had secured coverage for approximately 166 million individuals through a combination of government and commercial payer agreements, a coverage footprint the company has been actively expanding throughout the year.